Literature DB >> 23232070

The Fra-2 transgenic mouse model of systemic sclerosis.

Britta Maurer1, Jörg H W Distler, Oliver Distler.   

Abstract

In systemic sclerosis, microvascular injury often precedes the development of fibrosis. Whereas the development of digital ulcers and skin fibrosis causes high morbidity, the affection of internal organs, in particular complications such as interstitial lung disease and pulmonary (arterial) hypertension, account for the high disease-associated mortality of these patients. Vascular animal models of systemic sclerosis are of utmost importance to study pathophysiological aspects, to identify molecular key players, and to perform interventional proof of concept-studies. So far, animal models of systemic sclerosis have mainly reflected the pro-fibrotic features of the human disease. The Fra-2 (Fos-related antigen-2) transgenic mouse model simultaneously displays both pro-fibrotic and vascular characteristics of human systemic sclerosis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23232070     DOI: 10.1016/j.vph.2012.12.001

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  19 in total

Review 1.  Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

Authors:  Oliver Distler; Antonio Cozzio
Journal:  Semin Immunopathol       Date:  2015-11-17       Impact factor: 9.623

Review 2.  Origin of fibrosing cells in systemic sclerosis.

Authors:  Sarah Ebmeier; Valerie Horsley
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

Review 3.  The immunopathology of lung fibrosis: amphiregulin-producing pathogenic memory T helper-2 cells control the airway fibrotic responses by inducing eosinophils to secrete osteopontin.

Authors:  Kiyoshi Hirahara; Ami Aoki; Yuki Morimoto; Masahiro Kiuchi; Mikiko Okano; Toshinori Nakayama
Journal:  Semin Immunopathol       Date:  2019-04-09       Impact factor: 9.623

Review 4.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 5.  Macrophages in Systemic Sclerosis: Novel Insights and Therapeutic Implications.

Authors:  Diana M Toledo; Patricia A Pioli
Journal:  Curr Rheumatol Rep       Date:  2019-05-23       Impact factor: 4.592

6.  Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors.

Authors:  Roberta Goncalves Marangoni; Benjamin D Korman; Jun Wei; Tammara A Wood; Lauren V Graham; Michael L Whitfield; Philipp E Scherer; Warren G Tourtellotte; John Varga
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

Review 7.  Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance.

Authors:  Benjamin D Korman; Lindsey A Criswell
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 8.  Animal models of systemic sclerosis: their utility and limitations.

Authors:  Carol M Artlett
Journal:  Open Access Rheumatol       Date:  2014-07-01

9.  The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis.

Authors:  Ariella Zehender; Jingang Huang; Andrea-Hermina Györfi; Alexandru-Emil Matei; Thuong Trinh-Minh; Xiaohan Xu; Yi-Nan Li; Chih-Wei Chen; Jianping Lin; Clara Dees; Christian Beyer; Kolja Gelse; Zhong-Yin Zhang; Christina Bergmann; Andreas Ramming; Walter Birchmeier; Oliver Distler; Georg Schett; Jörg H W Distler
Journal:  Nat Commun       Date:  2018-08-14       Impact factor: 14.919

Review 10.  Unraveling SSc Pathophysiology; The Myofibroblast.

Authors:  Arjan van Caam; Madelon Vonk; Frank van den Hoogen; Peter van Lent; Peter van der Kraan
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.